These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 16914770)
1. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. Gaidukov L; Rosenblat M; Aviram M; Tawfik DS J Lipid Res; 2006 Nov; 47(11):2492-502. PubMed ID: 16914770 [TBL] [Abstract][Full Text] [Related]
2. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. Rosenblat M; Gaidukov L; Khersonsky O; Vaya J; Oren R; Tawfik DS; Aviram M J Biol Chem; 2006 Mar; 281(11):7657-65. PubMed ID: 16407304 [TBL] [Abstract][Full Text] [Related]
3. ApoE induces serum paraoxonase PON1 activity and stability similar to ApoA-I. Gaidukov L; Viji RI; Yacobson S; Rosenblat M; Aviram M; Tawfik DS Biochemistry; 2010 Jan; 49(3):532-8. PubMed ID: 20025294 [TBL] [Abstract][Full Text] [Related]
4. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Gaidukov L; Tawfik DS Biochemistry; 2005 Sep; 44(35):11843-54. PubMed ID: 16128586 [TBL] [Abstract][Full Text] [Related]
5. The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity. Gaidukov L; Tawfik DS J Lipid Res; 2007 Jul; 48(7):1637-46. PubMed ID: 17435182 [TBL] [Abstract][Full Text] [Related]
7. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Rosenblat M; Karry R; Aviram M Atherosclerosis; 2006 Jul; 187(1):74-81. PubMed ID: 16229851 [TBL] [Abstract][Full Text] [Related]
8. The Association of the Cholesterol Efflux Capacity with the Paraoxonase 1 Q192R Genotype and the Paraoxonase Activity. Oniki K; Ohura K; Endo M; Akatwijuka D; Matsumoto E; Nakamura T; Ogata Y; Yoshida M; Harada-Shiba M; Saruwatari J; Ogura M; Imai T J Atheroscler Thromb; 2024 Sep; 31(9):1263-1276. PubMed ID: 38508740 [TBL] [Abstract][Full Text] [Related]
9. Macrophage paraoxonase 1 (PON1) binding sites. Efrat M; Aviram M Biochem Biophys Res Commun; 2008 Nov; 376(1):105-10. PubMed ID: 18762170 [TBL] [Abstract][Full Text] [Related]
10. High-density lipoprotein cholesterol and paraoxonase 1 (PON1) genetics and serum PON1 activity in prepubertal children in Spain. Garcés C; López-Simón L; Rubio R; Benavente M; Cano B; Ortega H; de Oya M Clin Chem Lab Med; 2008; 46(6):809-13. PubMed ID: 18601602 [TBL] [Abstract][Full Text] [Related]
11. The PON1 M55L gene polymorphism is associated with reduced HDL-associated PAF-AH activity. Kakafika AI; Xenofontos S; Tsimihodimos V; Tambaki AP; Lourida ES; Kalaitzidis R; Cariolou MA; Elisaf M; Tselepis AD J Lipid Res; 2003 Oct; 44(10):1919-26. PubMed ID: 12867538 [TBL] [Abstract][Full Text] [Related]
12. Paraoxonase 1 interactions with HDL, antioxidants and macrophages regulate atherogenesis - a protective role for HDL phospholipids. Efrat M; Aviram M Adv Exp Med Biol; 2010; 660():153-66. PubMed ID: 20221878 [TBL] [Abstract][Full Text] [Related]
13. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential. Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641 [TBL] [Abstract][Full Text] [Related]
14. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Rosenblat M; Vaya J; Shih D; Aviram M Atherosclerosis; 2005 Mar; 179(1):69-77. PubMed ID: 15721011 [TBL] [Abstract][Full Text] [Related]
15. HDL3 stimulates paraoxonase 1 antiatherogenic catalytic and biological activities in a macrophage model system: in vivo and in vitro studies. Rosenblat M; Volkova N; Aviram M Biofactors; 2014; 40(5):536-45. PubMed ID: 25230879 [TBL] [Abstract][Full Text] [Related]
16. Associations between HDL oxidation and paraoxonase-1 and paraoxonase-1 gene polymorphisms in families affected by familial combined hyperlipidemia. Liu ML; James RW; Ylitalo K; Taskinen MR Nutr Metab Cardiovasc Dis; 2004 Apr; 14(2):81-7. PubMed ID: 15242240 [TBL] [Abstract][Full Text] [Related]
17. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. Mackness B; Mackness MI; Arrol S; Turkie W; Durrington PN FEBS Lett; 1998 Feb; 423(1):57-60. PubMed ID: 9506841 [TBL] [Abstract][Full Text] [Related]
18. The effect of HDL-bound and free PON1 on copper-induced LDL oxidation. Bayrak A; Bayrak T; Bodur E; Kılınç K; Demirpençe E Chem Biol Interact; 2016 Sep; 257():141-6. PubMed ID: 27510818 [TBL] [Abstract][Full Text] [Related]
19. How HDL protects LDL against atherogenic modification: paraoxonase 1 and other dramatis personae. Soran H; Schofield JD; Liu Y; Durrington PN Curr Opin Lipidol; 2015 Aug; 26(4):247-56. PubMed ID: 26103614 [TBL] [Abstract][Full Text] [Related]